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Auriculocondylar syndrome (ACS) is a rare craniofacial disorder with mandibular hypoplasia and question-mark ears (QMEs) as major
features. QMEs, consisting of a specific defect at the lobe-helix junction, can also occur as an isolated anomaly. Studies in animal models
have indicated the essential role of endothelin 1 (EDN1) signaling through the endothelin receptor type A (EDNRA) in patterning the
mandibular portion of the first pharyngeal arch. Mutations in the genes coding for phospholipase C, beta 4 (PLCB4) and guanine nucle-
otide binding protein (G protein), alpha inhibiting activity polypeptide 3 (GNAI3), predicted to function as signal transducers down-
stream of EDNRA, have recently been reported in ACS. By whole-exome sequencing (WES), we identified a homozygous substitution
in a furin cleavage site of the EDN1 proprotein in ACS-affected siblings born to consanguineous parents. WES of two cases with vertical
transmission of isolated QMEs revealed a stopmutation in EDN1 in one family and amissense substitution of a highly conserved residue
in the mature EDN1 peptide in the other. Targeted sequencing of EDN1 in an ACS individual with related parents identified a fourth,
homozygous mutation falling close to the site of cleavage by endothelin-converting enzyme. The different modes of inheritance suggest
that the degree of residual EDN1 activity differs depending on the mutation. These findings provide further support for the hypothesis
that ACS and QMEs are uniquely caused by disruption of the EDN1-EDNRA signaling pathway.Neural crest cells (NCCs) are a transient embryonic popula-
tion whose derivatives make major contributions to the
skeletal and connective tissue of the face, the cardiac
outflow tract, the peripheral and enteric nervous systems,
and melanocytes. The endothelin system, consisting of
three peptide ligands (endothelins 1, 2, and 3, encoded
by EDN1 [MIM 131240], EDN2 [MIM 131241], and EDN3
[MIM 131242], respectively) and two G-protein-coupled
seven transmembrane domain receptors (endothelin re-
ceptors type A and B, encoded by EDNRA [MIM 131243]
and EDNRB [MIM 131244], respectively), plays key roles
in the development of various NCC derivatives. In hu-
mans, mutations in EDN3 and EDNRB cause Waardenburg
syndrome, type 4 (WS4 [MIM 277580 and 613265]), a
disorder involving enteric and melanocytic NCCs and
comprising Hirschsprung disease, pigmentation defects,
and hearing loss (reviewed in Pingault et al.1). Studies in
animal models have highlighted the importance of the
EDN1-EDNRA signaling pathway in the development of
the lower jaw. During early stages of craniofacial morpho-
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arches (PAs), where they receive cues from surrounding tis-
sues that promote patterning and differentiation (reviewed
in Cordero et al.2). The first PA is divided into maxillary
and mandibular prominences, from which the skeleton
of the upper and lower jaws will arise, respectively, whereas
the external ear is derived from a series of swellings that
surround the cleft between the first and second PAs (re-
viewed in Passos-Bueno et al.3). Edn1 is expressed from
the epithelium of the mandibular prominence of the first
PA and caudal PAs,4 where the EDN1 peptide signals to
underlying ectomesenchyme by stimulating EDNRA on
cranial NCCs. Mice with a targeted deletion of Edn1, Ednra,
or endothelin-converting enzyme 1 (Ece1, encoding an
enzyme involved in EDN1 cleavage) display severe defects
in mandibular development, in which changes in skeletal
morphology are consistent with a homeotic transforma-
tion of the lower jaw into an upper jaw, as well as defects
of the cardiovascular system.5–10 In an ENU screen in
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Table 1. Clinical Features of Individuals Studied in This Report
Identity in Present Report
F1:II-1 F1:II-3 F1:II-4 F2:I-2 F2:II-2 F3:III-2 F3:IV-1 F3:IV-2 S1:II-1
Identity in
previous
publication
case 10
(Gordon
et al.12)
case 10
(Gordon
et al.12)
 case 11
(Gordon
et al.12)
case 11
(Gordon
et al.12)
case 12
(Gordon
et al.12)
case 12
(Gordon
et al.12)
case 12
(Gordon
et al.12)
patient 2 (Guion-
Almeida et al.16)
Inheritance AR AR AR AD AD AD AD AD AR
Diagnosis ACS ACS ACS IQMEs IQMEs IQMEs IQMEs IQMEs ACS
Gender male female female female female female male female male
QMEs þ þ þ þ þ þ þ þ þ
Micrognathia
and/or
retrognathia
þ þ þ      þ
Oral
anomalies
bifid uvula,
laryngeal
cleft
glossoptosis bifid and ectopic
uvula, lingual
hamartomas,
submucosal
velar cleft
     ectopic
tonsillar and
lingual
appendages
Other
phenotypes
vein of Galen
dilation
bilateral
conductive
hearing loss
with narrow
auditory
canals
  reduced
thyroid
function
  acute
lymphoblastic
leukemia
ptosis, ectropion,
intellectual
disability,
sleep apnea,
white-matter
hyperintensities
EDN1
mutation
c.271A>G c.271A>G c.271A>G c.191T>A c.191T>A c.249T>G not
tested
c.249T>G c.230C>A
Protein
change
p.Lys91Glu p.Lys91Glu p.Lys91Glu p.Val64Asp p.Val64Asp p.Tyr83*  p.Tyr83* p.Pro77His
Abbreviations are as follows: ACS, auriculocondylar syndrome; AD, autosomal dominant; AR, autosomal recessive; and IQME, isolated question-mark ear.defects in the skeletal elements of the lower jaw.11 Muta-
tions in human EDN1 or EDNRA are currently absent
from publically available databases.
Auriculocondylar syndrome (ACS [MIM 602483 and
614669]) is a rare craniofacial disorder involving first and
second PA derivatives and has key features of microgna-
thia, temporomandibular joint and condyle anomalies,
microstomia, prominent cheeks, and question-mark ears
(QMEs).12 QMEs consist of a defect between the lobe and
the upper two-thirds of the pinna, range from a mild
indentation in the helix to a complete cleft between the
lobe and helix, and have been reported in individuals
without mandibular defects (isolated QMEs [IQMEs]
[MIM 612798]). Mutations in phospholipase C, beta 4
(PLCB4 [MIM 600810]) and guanine nucleotide binding
protein (G protein), alpha inhibiting activity polypeptide
3 (GNAI3 [MIM 139370]), have been identified in the
majority of ACS cases.12–14 Heterozygous missense substi-
tutions, some of which represent hot spots, have been
found within the catalytic domain of each protein and
are predicted to result in dominant-negative effects on
the wild-type version of each protein or other proteins.
In addition, two cases have been ascribed to homozygous
or compound-heterozygous loss-of-function mutations in
PLCB4.12,14 It has been hypothesized that PLCB4 and
GNAI3 function as signal transducers within the EDN1-The American JouEDNRA pathway. This is based on (1) the known involve-
ment of G proteins and phospholipase C enzymes in
endothelin signaling in other contexts, (2) the genetic
interaction between edn1 and plcb3 (an ortholog of
PLCB4) in zebrafish craniofacial development,15 (3) the
demonstration that known EDNRA target genes DLX5
(MIM 600028) and DLX6 (MIM 600030) are downregu-
lated in osteoblasts from PLCB4- or GNAI3-mutated ACS
individuals, and (4) the interpretation of the abnormal
mandibular skeleton in ACS as a mandibular-to-maxillary
homeotic transformation, as for that of Edn1- or Ednra-
null mice.13
After a screen for PLCB4 or GNAI3 mutations in a series
of 11 ACS and IQME index cases, we were unable to iden-
tify a mutation or deletion at either locus in only three
(cases 10, 11, and 12 in Gordon et al.12 and hereafter
referred to as families F1, F2, and F3, respectively). Their
clinical features are summarized in Table 1. F1 consists of
consanguineous healthy parents, one unaffected child,
and three ACS-affected siblings (Figures 1A and 2).
Although the F1 father’s earlobes are mildly anteverted,
this feature was not considered related to his children’s
auricular phenotype. A computed-tomography (CT) scan
of F1 individual II:3 revealed hypoplasia of the mandibular
ramus and a thickened zygomatic process of the right tem-
poral bone (Figure 1A). F1 individual II:4, previouslyrnal of Human Genetics 93, 1118–1125, December 5, 2013 1119
B (family F2)
I:2
II:2
III:2                IV:2 IV:1
III:2               IV:2 IV:1
C  (family F3)
A (family F1)
II:1                  II:1               II:1  
II:3              II:3                                       II:3  II:3  
II:4 II:4 I:2 I:1
Figure 1. Craniofacial Features of ACS and IQME Individuals
Families F1 (A), F2, (B), and F3 (C). The numbering of individuals
refers to the pedigrees in Figure 2. In (A), right and left lateral CT
scans of individual II:3 are presented (black arrows indicate prox-
imal mandibular hypoplasia, and the white arrow indicates the
thickened zygomatic process of the right temporal bone), and
an intraoral view of individual II:4 depicts the bifid uvula with
adjacent ectopic tissue.unreported, presented with micrognathia, QMEs, micro-
stomia, full cheeks, several small hamartomatous pedicles
on the ventral surface of the tongue, a bilateral paramedian
submucosal cleft of the velum, and a bifid uvula with
ectopic tissue beside it (Figure 1A). Families F2 and F3
each consist of individuals with dominantly inherited
IQMEs: an affectedmother and daughter in F2 and affected
individuals through four generations in F3 (Figures 1B, 1C,
and 2). To identify coding variants responsible for ACS and
IQMEs in families F1–F3, we performed whole-exome
sequencing on two affected siblings from F1 (II:1 and
II:3), under the assumption that each shares recessive
alleles by descent, and one individual from each of F2
and F3 (I:2 and III:2, respectively), under the assumption
that they harbor variants in the same gene or in genes
plausibly linked to the EDN1-EDNRA pathway. Approval
for human genetic research was obtained from the Comite´
de Protection des Personnes Ile-de-France II, and partici-
pants gave their written informed consent for genetic1120 The American Journal of Human Genetics 93, 1118–1125, Decestudies. Agilent SureSelect libraries were prepared from
3 mg of genomic DNA sheared with a Covaris
S2 Ultrasonicator as recommended by the manufacturer.
Exome capture was performed with the 51 Mb SureSelect
Human All Exon Kit V5 (Agilent technologies) via a multi-
plex approach with molecular barcodes for traceable iden-
tity of samples. Sequencing was carried out on a pool of
barcoded exome libraries with either a SOLiD5500XL
(Life technologies) or a HiSeq2500 (Illumina) machine.
75þ35 bp paired-end reads were generated with the SOL-
iD5500XL, and 76þ76 bp paired-end reads were generated
with the HiSeq2500. After demultiplexing, paired-end se-
quences were aligned to the reference human genome
(hg19, UCSC Genome Browser) with LifeScope (Life Tech-
nologies) for SOLiD data and with the Burrows-Wheeler
Aligner17 for Illumina data. The mean depth of coverage
obtained for each sample was greater than 803, and
more than 90% of the exome was covered at least 153.
Downstream processing was carried out with the Genome
Analysis Toolkit (GATK),18 SAMtools,19 and Picard accord-
ing to documented best practices. Variant calls were made
with the GATK Unified Genotyper. All calls with read
coverage %23 or a Phred-scaled SNP quality score of %
20 were removed from consideration. An in-house soft-
ware system (PolyWeb) developed by the Plateforme Bio-
informatique of Universite´ Paris Descartes was used for
annotating variants (based on Ensembl release 71)20 and
filtering variants according to relevant genetic models in
each case. We excluded known variants listed in the public
databases dbSNP (build 135), the National Heart, Lung,
and Blood Institute (NHLBI) Exome Sequencing Project
Exome Variant Server (release ESP6500SI-V2), and 1000
Genomes (release date May 21, 2011) and variants previ-
ously identified in more than 3,000 in-house exomes. We
then selected variants affecting splice sites or coding re-
gions (nonsynonymous substitutions, insertions, or dele-
tions). Upon applying these criteria to each exome of the
two affected F1 siblings and selecting for homozygous var-
iants shared by both individuals, a single variant remained:
c.271A>G (p.Lys91Glu) in EDN1 (RefSeq accession num-
ber NM_001955.4). Analysis of the distribution of variants
in the exome data indicated that EDN1 falls within a
shared homozygosity run of 9–12 Mb in the two siblings.
After the same criteria as above were applied to each F2
and F3 exome (but only genes in which both individuals
harbored a filtered heterozygous variant were selected),
27 variants in 12 genes were identified. From this list,
only those variants predicted to be deleterious by both Pol-
yPhen and SIFT programs were retained. Variants in two
genes met these criteria: PLXNB3 (MIM 300214) and
EDN1. The two variants in PLXNB3 (RefSeq
NM_005393.2) were c.4141C>T (p.Leu1381Phe) (F2 indi-
vidual) and c.4751G>A (p.Gly1584Asp) (F3 individual),
but PLXNB3 was not considered further given the absence
of data supporting a role for this gene in craniofacial devel-
opment, its localization on the X chromosome, and the ex-
istence of recurrent frameshift variants listed in the NHLBImber 5, 2013
Figure 2. EDN1 Mutations and Their
Segregation in ACS- or IQME-Affected
Families F1–F3 and Simplex Case S1
‘‘EX’’ indicates those individuals submitted
to exome sequencing. The relevant EDN1
genotype is indicated for all those individ-
uals whose DNA was available for testing.Exome Variant Server. The EDN1 mutations identified
were c.191T>A (p.Val64Asp) for the F2 individual and
c.249T>G (p.Tyr83*) for the F3 individual. Each EDN1mu-
tation was validated by Sanger sequencing and segregated
according to phenotype and mode of inheritance in each
individual available for study in F1, F2, and F3 (Figure 2).
In family F1, the unaffected parents and child were
heterozygous for the mutation, whereas the three affected
siblings were homozygous, indicating that the allele en-
coding the p.Lys91Glu substitution behaves in a recessive
manner. Alternatively, in families F2 and F3, the mutations
were present in affected members of each generation,
indicating that the alleles encoding the p.Val64Asp and
p.Tyr83* substitutions behave dominantly. Finally, we
tested EDN1 directly in a previously published simplex
case of an ACS individual born to consanguineous parents
(patient 2 in Guion-Almeida et al.,16 hereafter referred to
as S1; see Table 1). In addition to showing typical ACS fea-
tures, he has tonsillar appendages16 and previously unre-
ported sublingual appendices. He has mild bilateral ptosis
and mild bilateral ectropion. As an adult, S1 has mild intel-
lectual disability, obstructive respiratory distress, and sleep
apnea. At age 23 years, hyperintensities in centrum semio-
vale and subcortical white matter were observed upon
T2-weighted and fluid-attenuated inversion recovery
MRI. Sanger sequencing revealed a private, homozygous
c.230C>A (p.Pro77His) mutation in EDN1 (Figure 2). S1’s
unaffected mother was heterozygous for the variant,
consistent with the recessive nature of this allele.
EDN1, first identified in 1988 as a potent vasocon-
strictor,21 is translated as a 212 amino acid preproproteinThe American Journal of Human Geneticthat undergoes a series of proteolytic
processing events: cleavage by a
signal peptidase to produce proEDN1,
cleavage by furin at two sites in pro-
EDN1 to liberate the 38 amino acid bi-
gEDN1, and cleavage of bigEDN1 by
ECE enzymes to produce the mature,
bioactive EDN1 peptide of 21 amino
acids (Figure 3). Furin, a member of
the proprotein convertase family,
cleaves a wide range of target proteins
at basic amino acid consensus sites,
several of which are altered in human
diseases (reviewed in Thomas28 and
Nakayama29). Furin cleavage occurs
immediately C-terminally to each of
two four-residue consensus sites inproEDN1: Arg-Ser-Lys-Arg (with amino acid position
nomenclature P-4, P-3, P-2, and P-1, respectively)
(Figure 3). The p.Lys91Glu substitution in family F1 affects
the lysine at position P-2 in the C-terminal proEDN1 furin
recognition site (Figure 3). A basic amino acid (either lysine
or arginine) occurs at the P-2 position of EDN1 in all
sequenced vertebrates (according to the Multiz alignment
in the UCSC Genome Browser), whereas the F1 substitu-
tion (glutamic acid) is an acidic amino acid. The sensitivity
of the furin recognition sites in endothelins to disruption
is highlighted by substitutions at the P-4 and P-1 positions
in proEDN3 in WS4 cases and in mouse lines with WS4-
like phenotypes1,22,26,27 (Figure 3). Furthermore, a muta-
tion resulting in substitution of the P-2 lysine of the furin
recognition site in ectodysplasin A (encoded by EDA [MIM
300451]) has been identified in X-linked hypohidrotic
ectodermal dysplasia (MIM 305100).30,31 In vitro assays
of the ability of furin to cleave mutagenized substrates
have indicated that the P-4 and P-1 sites are critical for
cleavage, whereas the P-2 site is either as sensitive to
disruption as P-4 and P-130 or less sensitive but nonetheless
required for maximal furin activity.32–35 The above studies
strongly support a causal role for the p.Lys91Glu substitu-
tion in the phenotype of affected F1 family members.
Active endothelin peptides are stabilized by two intramo-
lecular disulphide bridges—one between Cys1 and Cys15
and one between Cys3 and Cys11 (numbering from the
start of the mature 21 amino acid peptide; see Figure 3).
The valine substituted by aspartic acid in family F2 corre-
sponds toVal12 inmature EDN1and is adjacent to the third
cysteine. A valine at this position is highly conserved ins 93, 1118–1125, December 5, 2013 1121
Figure 3. PreproEDN1 Domain Structure
and Positions of Amino Acids Affected by
Mutations
In the diagram at the top, bigEDN1 is
shown in two shades of gray (the mature
21 amino acid peptide is the darker shade).
Open arrowheads indicate furin cleavage
sites. A filled arrowhead indicates the ECE
cleavage site. Red arrows indicate the posi-
tions of substitutions identified in this
report. The lower part of the figure is a
multiple-sequence alignment of big endo-
thelins and surrounding furin cleavage
sites from selected species. Sequences
used in the alignment were human
EDN1 (RefSeq NP_001946.3), mouse
EDN1 (RefSeq NP_034234.1), zebrafish
Edn1 (RefSeq NP_571594.1), human
EDN3 (RefSeq NP_000105.1), and
mouse EDN3 (RefSeq NP_031929.1). The
numbering above the alignment refers to
the 21 amino acid mature peptide.
Residues underlined with a red bar are affected by mutations in human EDN1 (this report), zebrafish edn1,11 human EDN3,1,22–25 and
mouse Edn326,27 (see text for details). Black bars under the alignment indicate the two four-residue furin recognition sites. SP stands
for signal peptide.EDN1, EDN2, and EDN3 in vertebrates. In an alanine-scan-
ningmutagenesis study of EDN1, a p.Val12Ala substitution
resulted in a peptide with binding capacity 16% of that of
wild-type EDN1 in a cell-based binding assay and with
agonist activity 29% of that of wild-type EDN1 in a rabbit
vena cava organ-bath-culture contractility assay.36 Note
that a valine-to-alanine substitution is a less chemically dis-
similar change than the valine-to-aspartic-acid substitution
identified in F2 (Grantham scores of 64 versus 152, respec-
tively37); thus, the effect of the F2 mutation might be
more severe than that predicted by the alanine-scanning
study. Notably, themissense substitution in Edn1 in the ze-
brafish craniofacialmutant sucker falls atAsp8of themature
peptide11 (Figure 3). Considering EDN3, substitutions
affecting Thr2 (two different alterations) and His16 in the
mature peptide have been identified in individuals with
WS41,23,24 (Figure 3). Collectively these studies highlight
the sensitivity of mature endothelin peptides to substitu-
tions and support the pathogenicity of the EDN1 missense
substitution in family F2. The p.Tyr83* substitution in fam-
ily F3 falls within bigEDN1 and is C-terminal to the mature
peptide in the region encoded by the third of the five exons
of EDN1, presumably leading to a null allele via nonsense-
mediated decay. p.Pro77His, the homozygous substitution
in individual S1, also falls within bigEDN1 and is four
amino acids C-terminal to the site of cleavage by ECE
enzymes (Figure 3). A proline at this position is highly
conserved in endothelin paralogs. In a mutagenesis study
of selected residues in the C-terminal portion of bigEDN1,
substitution of Pro77 (Pro25 numbering from the start of
bigEDN1) to alanine resulted in a significant reduction in
the conversion of bigEDN1 to EDN1, as assayed in the me-
dia of cells transfected with plasmids encoding wild-type or
altered preproEDN1 and ECE1.38 In addition, p.Pro25Ala-
transfected cells had less total recombinant protein
(bigEDN1 plus EDN1)measured in themedia than did cells1122 The American Journal of Human Genetics 93, 1118–1125, Decetransfected with wild-type preproEDN1, suggesting that
this proline might play a role in bigEDN1 stability. These
data argue that the p.Pro77His substitution in individual
S1 is pathogenic.
The craniofacial phenotypes observed in the EDN1-
mutated individuals reported here are consistent with,
albeit less severe than, those of Edn1-homozygous-null
mice, which demonstrated mandibular and auricular
hypoplasia and cleft palate.5 As discussed below, the F1
and S1 EDN1 alleles might be hypomorphic, accounting
for the fact that their phenotype was less severe in the ho-
mozygous state than that of Edn1-homozygous-null mice.
In ACS, the mandible is most severely affected proximally,
and hypoplasia of the condyle and the ramus are typical
findings. A CT scan of individual II:3 in family F1 also
indicated proximal mandibular hypoplasia. Interestingly,
some mouse models with partially reduced dosage of
various components of the EDN1 pathway display more
severe defects in proximal regions of the mandible than
in distal regions, as demonstrated, for example, in mice
with combined heterozygous loss of Edn1, Dlx5, and
Dlx639 and in Ednra/ mice in which a knockin of the
Ednrb cDNA at the Ednra locus rescues only distal regions
of the mandibular phenotype.40 The morphology of the
mandible in Edn1/ and Ednra/ mice is consistent
with a homeotic transformation of the lower jaw into an
upper-jaw-like structure,9,10 and a similar transformation
has been proposed in individuals with mutations in
PLCB4 and GNAI3.13 Soft-tissue changes on the floor of
the oral cavity in Ednra/mice were suggestive of ectopic
palatal rugae.10 Notably, ectopic sublingual, uvular, and
tonsillar appendages were observed here in F1 and S1 indi-
viduals and previously in cases with PLCB4 and GNAI3
mutations,12,13 although it remains unclear whether these
structures are related to a mandibular-to-maxillary identity
switch. Edn1-knockout mice also display cardiac defectsmber 5, 2013
with incomplete penetrance.6 No congenital heart defects
were identified upon echocardiography in individuals II:1
and II:3 of family F1 (the other individuals in this report
did not present with symptoms of cardiac defects). Individ-
ual II:1 in family F1 presented with an aneurismal dilation
of the vein of Galen, associated with two arteriovenous
fistulae, but it remains unclear whether this was related
to his EDN1 mutation.
The different mode of inheritance for the F1 and S1
mutant EDN1 alleles compared to the F2 and F3 alleles
might be explained by differences in the amount of resid-
ual functional protein in each case. We suggest a model in
which heterozygous-null EDN1 alleles result in IQMEs and
in which hypomorphic alleles result in an ACS phenotype
in homozygotes and no phenotype in heterozygotes.
According to this model, homozygous EDN1 loss of func-
tion would lead to a more severe phenotype than classical
ACS. This model also suggests that, surprisingly, the
external ear is more sensitive than the mandible to pertur-
bations of EDN1 signaling in humans. However, it remains
possible that EDN1 mutations also underlie isolated
mandibular defects. Interestingly, homozygous EDN3 mu-
tations typically lead to WS4, comprising Hirschsprung
disease, hearing loss, and pigmentation defects, whereas
heterozygous carriers might display hearing loss and/or
pigmentation defects only.1,24 Rare cases of heterozygous
EDN3 mutations in WS4 or isolated Hirschsprung disease
have also been reported.41,42 This could indicate the
influence of modifying alleles on the phenotype associated
with EDN3mutations. It remains to be seen whether EDN1
mutations are also influenced by genetic background.
Indeed, incomplete penetrance has been observed in
several ACS cases with PLCB4 orGNAI3mutations. A larger
number of ACS and IQME cases harboring EDN1 muta-
tions will aid our understanding of the molecular basis of
the phenotypic variability reported here.
In conclusion, we have identified EDN1 as a third locus
for the ACS and IQME spectrum of disorders. Among the
PLCB4, GNAI3, and EDN1 loci, we have determined the
molecular bases of all phenotypically convincing ACS
and IQME cases screened at Hoˆpital Necker to date (a total
of 19 index cases from the present report, Gordon et al.,12
Rieder et al.,13 and Kido et al.,14 and unpublished data).
This suggests that any further genetic heterogeneity in
ACS will be rare. The small number of IQME cases tested
is not yet sufficient to exclude the possibility of other
loci for this anomaly. The finding that recessive EDN1
mutations result in ACS argues that the phenotype caused
by PLCB4 or GNAI3 mutations is due entirely to the effect
of these mutations on the EDN1-EDNRA pathway and
highlights the importance of this pathway for normal
craniofacial development in humans.Acknowledgments
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